Medical Prognosis Institute A/S - Passing of Extraordinary General Meeting

2014-09-02

Hoersholm; September 2, 2014 - On Tuesday 2 September 2014 at 3 p.m., an extraordinary general meeting of Medical Prognosis Institute A/S was held with the following agenda:

      1.       Motion from the board of directors to pass a resolution to authorize the board of directors to increase the company's share capital, including a motion to amend the company's articles of association accordingly

      2.       Authorisation to the chairman of the general meeting

      3.       Any other business

In accordance with article 10.2 of the company's articles of association, the board of directors appointed Attorney-at-Law Henriette Stakemann to chair the annual general meeting.

 

Re item 1

The general meeting granted the board of directors an authorization - in the period until 2 September 2019 - to increase the company's share capital once or several times by issuing new shares by up to nominally DKK 104,064. The increase of the share capital shall be effected by cash payment with a pre-emption right to the company's existing shareholders and at the market price or at a favourable price fixed by the board of directors.

Further, the general meeting granted the board of directors an authorisation for the same period of time to increase the company's share capital once or several times by issuing new shares by up to nominally DKK 100,000. The increase of the share capital shall be effected without any pre-emption right to the company's existing shareholders and at market price. The board of directors may decide that the increase is to be effected by cash payment, by contribution in kind or by debt conversion.

 

The general meeting resolved to incorporate the authorisations in the company's articles of association.

 

Re item 2

The general meeting authorized the chairman of the general meeting to register the resolutions with the Danish Business Authority.

 

Best regards

Medical Prognosis Institute A/S


For further information please contact
Peter Buhl Jensen, CEO
E-mail: pbj@medical-prognosis.com
Cell Phone: (+45) 21 60 89 22

Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark